Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy Read more about Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine Read more about Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) Read more about Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors Read more about Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies Read more about Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer Read more about An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer Read more about A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
Efficacy and Safety of Grass-SPIRE Registration Study Read more about Efficacy and Safety of Grass-SPIRE Registration Study
CTL019 Out of Specification MAP for ALL or DLBCL Patients Read more about CTL019 Out of Specification MAP for ALL or DLBCL Patients
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Read more about PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors